Home LiteratureArticle Details
PMID: 17975708 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration.

Journal of neuro-oncology ·Vol. 87 ·No. 1 ·2008-03-00 ·Pages 23-33

Bassi R, Giussani P, Anelli V, Colleoni T, Pedrazzi M, Patrone M, Viani P, Sparatore B, Melloni E, Riboni L

Abstract

HMGB1 (high mobility group box 1 protein) is a nuclear protein that can also act as an extracellular trigger of inflammation, proliferation and migration, mainly through RAGE (the receptor for advanced glycation end products); HMGB1-RAGE interactions have been found to be important in a number of cancers. We investigated whether HMGB1 is an autocrine factor in human glioma cells. Western blots showed HMGB1 and RAGE expression in human malignant glioma cell lines. HMGB1 induced a dose-dependent increase in cell proliferation, which was found to be RAGE-mediated and involved the MAPK/ERK pathway. Moreover, in a wounding model, it induced a significant increase in cell migration, and RAGE-dependent activation of Rac1 was crucial in giving the tumour cells a motile phenotype. The fact that blocking DNA replication with anti-mitotic agents did not reduce the distance migrated suggests the independence of the proliferative and migratory effects. We also found that glioma cells contain HMGB1 predominantly in the nucleus, and cannot secrete it constitutively or upon stimulation; however, necrotic glioma cells can release HMGB1 after it has translocated from the nucleus to cytosol. These findings provide the first evidence supporting the existence of HMGB1/RAGE signalling pathways in human glioblastoma cells, and suggest that HMGB1 may play an important role in the relationship between necrosis and malignancy in glioma tumours by acting as an autocrine factor that is capable of promoting the growth and migration of tumour cells.

MeSH Terms
Blotting, Western Brain Neoplasms/metabolism Cell Line, Tumor Cell Movement/physiology Cell Proliferation Glioblastoma/metabolism Glycation End Products, Advanced HMGB1 Protein/metabolism Humans Mitogen-Activated Protein Kinases/biosynthesis Necrosis/physiopathology Receptor for Advanced Glycation End Products Receptors, Immunologic/biosynthesis Signal Transduction/physiology
Chemicals
Glycation End Products, Advanced HMGB1 Protein Receptor for Advanced Glycation End Products Receptors, Immunologic Mitogen-Activated Protein Kinases
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Bassi Rosaria
Department of Medical Chemistry, Biochemistry and Biotechnology, University of Milan, Segrate, Milan, Italy.
Giussani Paola
Anelli Viviana
Colleoni Thomas
Pedrazzi Marco
Patrone Mauro
Viani Paola
Sparatore Bianca
Melloni Edon
Riboni Laura
References (49)
49 references, click to expand
  1. Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis.
    Neurosurgery. 2002 Jul;51(1):2-12; discussion 12-3 PMID: 12182418
  2. Molecular mechanisms in gliomagenesis.
    Adv Cancer Res. 2005;94:1-27 PMID: 16095998
  3. Molecular pathways triggering glioma cell invasion.
    Expert Rev Mol Diagn. 2006 Jul;6(4):613-26 PMID: 16824034
  4. High-mobility group box 1 (HMGB1) protein: friend and foe.
    Cytokine Growth Factor Rev. 2006 Jun;17(3):189-201 PMID: 16513409
  5. Akt protein kinase inhibits non-apoptotic programmed cell death induced by ceramide.
    J Biol Chem. 2002 Jan 25;277(4):2790-7 PMID: 11706021
  6. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma.
    FASEB J. 2003 Jul;17(10):1295-7 PMID: 12759333
  7. The ERK cascade: a prototype of MAPK signaling.
    Mol Biotechnol. 2005 Oct;31(2):151-74 PMID: 16170216
  8. Sphingosine-1-phosphate is released by cerebellar astrocytes in response to bFGF and induces astrocyte proliferation through Gi-protein-coupled receptors.
    Glia. 2006 Apr 15;53(6):621-30 PMID: 16470810
  9. Mini-review: The nuclear protein HMGB1 as a proinflammatory mediator.
    Eur J Immunol. 2004 Jun;34(6):1503-12 PMID: 15162419
  10. HMGB1-secreting capacity of multiple cell lineages revealed by a novel HMGB1 ELISPOT assay.
    J Leukoc Biol. 2007 Jan;81(1):129-36 PMID: 16980509
  11. An essential role for Rac in Ras transformation.
    Nature. 1995 Mar 30;374(6521):457-9 PMID: 7700355
  12. Chromatin and cell death.
    Biochim Biophys Acta. 2004 Mar 15;1677(1-3):181-6 PMID: 15020058
  13. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer.
    Oncol Rep. 2003 Mar-Apr;10(2):445-8 PMID: 12579287
  14. Amphoterin as an extracellular regulator of cell motility: from discovery to disease.
    J Intern Med. 2004 Mar;255(3):351-66 PMID: 14871459
  15. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition.
    Oncogene. 2007 May 14;26(22):3227-39 PMID: 17496918
  16. Biological mechanisms of glioma invasion and potential therapeutic targets.
    J Neurooncol. 2001 Jun;53(2):129-47 PMID: 11716066
  17. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis.
    Cancer Res. 2002 Aug 15;62(16):4805-11 PMID: 12183440
  18. Expression of poly(ADP-ribose) polymerase and distribution of poly(ADP-ribosyl)ation in glioblastoma and in a glioma multicellular tumour spheroid model.
    Neuropathol Appl Neurobiol. 2000 Dec;26(6):528-35 PMID: 11123719
  19. Dichotomy of astrocytoma migration and proliferation.
    Int J Cancer. 1996 Jul 17;67(2):275-82 PMID: 8760599
  20. New advances on structural and biological functions of ceramide in apoptotic/necrotic cell death and cancer.
    FEBS Lett. 2002 Oct 23;530(1-3):9-16 PMID: 12387858
  21. Molecular changes in gliomas.
    Curr Opin Oncol. 2004 Nov;16(6):607-13 PMID: 15627025
  22. Understanding RAGE, the receptor for advanced glycation end products.
    J Mol Med (Berl). 2005 Nov;83(11):876-86 PMID: 16133426
  23. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases.
    Nature. 2000 May 18;405(6784):354-60 PMID: 10830965
  24. Down-regulation of the receptor for advanced glycation end-products (RAGE) supports non-small cell lung carcinoma.
    Carcinogenesis. 2005 Feb;26(2):293-301 PMID: 15539404
  25. Roles of the Rac1 and Rac3 GTPases in human tumor cell invasion.
    Oncogene. 2005 Nov 24;24(53):7821-9 PMID: 16027728
  26. Secretion and binding of HMG1 protein to the external surface of the membrane are required for murine erythroleukemia cell differentiation.
    FEBS Lett. 1997 Jan 6;400(3):275-9 PMID: 9009213
  27. Masquerader: high mobility group box-1 and cancer.
    Clin Cancer Res. 2007 May 15;13(10):2836-48 PMID: 17504981
  28. Significant (re)location: how to use chromatin and/or abundant proteins as messages of life and death.
    Trends Cell Biol. 2004 Jun;14(6):287-93 PMID: 15183185
  29. The WHO classification of tumors of the nervous system.
    J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 PMID: 11895036
  30. The cytokine activity of HMGB1.
    J Leukoc Biol. 2005 Jul;78(1):1-8 PMID: 15734795
  31. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal.
    Nat Rev Immunol. 2005 Apr;5(4):331-42 PMID: 15803152
  32. Regulation of cell migration by amphoterin.
    J Cell Sci. 2000 Feb;113 ( Pt 4):611-20 PMID: 10652254
  33. Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages.
    Am J Pathol. 2005 Mar;166(3):751-60 PMID: 15743787
  34. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function.
    J Intern Med. 2004 Mar;255(3):332-43 PMID: 14871457
  35. Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy.
    Curr Top Med Chem. 2005;5(2):215-29 PMID: 15853648
  36. Extracellular high-mobility group 1 protein is essential for murine erythroleukaemia cell differentiation.
    Biochem J. 1996 Nov 15;320 ( Pt 1):253-6 PMID: 8947495
  37. Activation of A431 human carcinoma cell motility by extracellular high-mobility group box 1 protein and epidermal growth factor stimuli.
    Biochem J. 2005 Jul 1;389(Pt 1):215-21 PMID: 15733057
  38. Biologically active sphingolipids in cancer pathogenesis and treatment.
    Nat Rev Cancer. 2004 Aug;4(8):604-16 PMID: 15286740
  39. Basic fibroblast growth factor-induced proliferation of primary astrocytes. evidence for the involvement of sphingomyelin biosynthesis.
    J Biol Chem. 2001 Apr 20;276(16):12797-804 PMID: 11278937
  40. The receptor for advanced glycation end-products (RAGE) directly binds to ERK by a D-domain-like docking site.
    FEBS Lett. 2003 Aug 28;550(1-3):107-13 PMID: 12935895
  41. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation.
    Nature. 2002 Jul 11;418(6894):191-5 PMID: 12110890
  42. Dealing with death: HMGB1 as a novel target for cancer therapy.
    Curr Opin Investig Drugs. 2003 Dec;4(12):1405-9 PMID: 14763124
  43. HMGB1: a signal of necrosis.
    Autoimmunity. 2007 Jun;40(4):285-9 PMID: 17516211
  44. Role of synaptojanin 2 in glioma cell migration and invasion.
    Cancer Res. 2004 Nov 15;64(22):8271-5 PMID: 15548694
  45. Activation of poly(ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus.
    J Biol Chem. 2007 Jun 15;282(24):17845-54 PMID: 17430886
  46. Extracellular role of HMGB1 in inflammation and sepsis.
    J Intern Med. 2004 Mar;255(3):320-31 PMID: 14871456
  47. Inhibition of Rho-kinase affects astrocytoma morphology, motility, and invasion through activation of Rac1.
    Cancer Res. 2005 Oct 1;65(19):8792-800 PMID: 16204049
  48. Protein measurement with the Folin phenol reagent.
    J Biol Chem. 1951 Nov;193(1):265-75 PMID: 14907713
  49. The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo.
    J Biol Chem. 2006 Mar 24;281(12):8242-53 PMID: 16407300
Article Info
Journal
Journal of neuro-oncology
Abbr.
J Neurooncol
ISSN
0167-594X
Published
2008-03-00
Epub
2007-00-02
Pages
23-33
Language
English
Region
United States
NLM ID
8309335
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com